0001209191-22-023285.txt : 20220405
0001209191-22-023285.hdr.sgml : 20220405
20220405182350
ACCESSION NUMBER: 0001209191-22-023285
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220401
FILED AS OF DATE: 20220405
DATE AS OF CHANGE: 20220405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galimi Francesco
CENTRAL INDEX KEY: 0001823996
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 22808674
MAIL ADDRESS:
STREET 1: 12930 VIA ESPERIA
CITY: DEL MAR
STATE: CA
ZIP: 92014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 CLARENDON STREET
STREET 2: FLOOR 6
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 CLARENDON STREET
STREET 2: FLOOR 6
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-01
0
0001720580
Adicet Bio, Inc.
ACET
0001823996
Galimi Francesco
C/O ADICET BIO, INC.
200 CLARENDON STREET, FLOOR 6
BOSTON
MA
02116
0
1
0
0
SVP & Chief Medical Officer
Common Stock
2022-04-01
4
M
0
7621
5.97
A
67538
D
Common Stock
2022-04-01
4
S
0
7621
21.00
D
59917
D
Common Stock
2022-04-04
4
M
0
6036
13.27
A
65953
D
Common Stock
2022-04-04
4
S
0
6036
21.00
D
59917
D
Common Stock
2022-04-04
4
M
0
168
5.97
A
60085
D
Common Stock
2022-04-04
4
S
0
168
21.00
D
59917
D
Common Stock
2022-04-04
4
M
0
1775
16.82
A
61692
D
Common Stock
2022-04-04
4
S
0
1775
21.00
D
59917
D
Employee Stock Option (Right to Buy)
5.97
2022-04-01
4
M
0
7621
D
2029-10-15
Common Stock
7621
113820
D
Employee Stock Option (Right to Buy)
13.27
2022-04-04
4
M
0
6036
0.00
D
2031-01-12
Common Stock
6036
73964
D
Employee Stock Option (Right to Buy)
5.97
2022-04-04
4
M
0
168
D
2029-10-15
Common Stock
168
113652
D
Employee Stock Option (Right to Buy)
16.82
2022-04-04
4
M
0
1775
0.00
D
2031-02-11
Common Stock
1775
26625
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021.
A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date.
Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."
A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.
A total of 28,400 shares subject to an employee stock option were granted on February 12, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.
/s/ Nick Harvey, Attorney-in-Fact
2022-04-05